AP24534

ponatinib · Ariad Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AP24534, covering 2018-05-16 to 2018-05-16. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies [Phase 1]

See pricing